A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
Public ClinicalTrials.gov record NCT03082209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously-Treated Solid Tumors and Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies. Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment.
Study identification
- NCT ID
- NCT03082209
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 153 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2017 (Actual)
- Primary completion
- Jan 21, 2022 (Actual)
- Completion
- Jan 21, 2022 (Actual)
- Last update posted
- Dec 9, 2022
2017 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale University /ID# 158029 | New Haven | Connecticut | 06510 | — |
| The University of Chicago Medical Center /ID# 158030 | Chicago | Illinois | 60637-1443 | — |
| Ingalls Memorial Hosp /ID# 171221 | Harvey | Illinois | 60426 | — |
| Univ Michigan Med Ctr /ID# 207134 | Ann Arbor | Michigan | 48109 | — |
| Rhode Island Hospital /ID# 171157 | Providence | Rhode Island | 02903 | — |
| Vanderbilt University Medical Center /ID# 215000 | Nashville | Tennessee | 37232-0011 | — |
| MD Anderson Cancer Center /ID# 202187 | Houston | Texas | 77030 | — |
| Millennium Oncology /ID# 214981 | Houston | Texas | 77090-1243 | — |
| South Texas Accelerated Research Therapeutics /ID# 160574 | San Antonio | Texas | 78229 | — |
| Medical College of Wisconsin /ID# 171152 | Milwaukee | Wisconsin | 53226-3522 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03082209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 9, 2022 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03082209 live on ClinicalTrials.gov.